Advances in the assessment of clinically localized prostate cancer

Eur Urol. 1996;29(3):257-65. doi: 10.1159/000473757.

Abstract

Objective: We review the advances in pathology, biology, and radiology which could improve the detection of extracapsular prostate cancer preoperatively.

Method: The experiences of others are compared to ours to give a topical overview of advances in the assessment of clinically localized prostate cancer.

Results: Despite new technologies, such as colour Doppler and endorectal magnetic resonance imaging, radiology does not enhance the ability to detect small invasion through the prostatic capsule. Biopsy features are one of the new fields of investigation. The number of positive sextant biopsies and the analysis of periprostatic spaces on biopsies appear to be major prognosis factors. In our experience, capsular perforation on biopsy is very powerful with respect to the proportion of positive biopsies ( > 66.7%) and serum PSA ( > 25 ng/ml, polyclonal assay) to predict biological progression after radical prostatectomy. The utility of the proportion of invaded tissue on biopsy is still debated.

Conclusions: Despite technical improvements, the staging of clinically confined prostate cancer is still a major issue. The best hope comes from the study of biopsy features in addition to PSA.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Biopsy
  • Humans
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / pathology
  • Magnetic Resonance Imaging
  • Male
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / genetics
  • Prostatectomy
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / pathology
  • Tomography, X-Ray Computed
  • Ultrasonography, Doppler, Color

Substances

  • Prostate-Specific Antigen